Brain

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

Increasing evidence supports a role for viral persistence, chronic inflammation and immune and metabolic dysregulation in driving long COVID Bezisterim,…

8 months ago

ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory

Key Accessory to the ClearPoint Prism® Neuro Laser Therapy Will Enable Operating Room Placement of Laser Fibers The ClearPoint Prism®…

8 months ago

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease

This publication, authored by leading experts in inflammasome-mediated inflammation and neurology at University of Miami Miller School of Medicine, demonstrates…

8 months ago

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

- Top-line Results Expected in the Second Half of 2024 -PURCHASE, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics,…

8 months ago

Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia

–   New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron   – MELBOURNE, Australia and SAN FRANCISCO,…

8 months ago

Solstice Pacific Residential Treatment Center Awarded Behavioral Health Care and Human Services Accreditation From the Joint Commission

Treatment of TBI and Mental Health Disorders in a High Service, Private Oceanside SettingSAN CLEMENTE, CA / ACCESSWIRE / April…

8 months ago

CompendiRx Unveils Innovative Approach to Long COVID: Empowering Patients Worldwide

NASHVILLE, TN / ACCESSWIRE / April 26, 2024 / The latest data from the US Census Bureau reflects alarming statistics…

8 months ago

Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready…

8 months ago

Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management

Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024…

8 months ago